Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 576 across all filing types
Latest filing 2022-05-11 Regulatory Filings
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2022-05-11 English
News release - English.pdf
Regulatory Filings
2022-05-10 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of the Results of Operations and Financial Condition' for the years ended December 31, 2021 and 2020. It includes detailed discussion of the company's operations, financial position, forward-looking statements, business overview, corporate updates, and management leadership changes. The presence of MD&A content, detailed financial and operational analysis, and discussion of results for a full fiscal year indicates this is a Management Discussion and Analysis report typically accompanying annual financial statements. This type of document is classified as a Management Reports (MDA) filing. The document length is substantial (15,000 characters), and it contains substantive financial and operational analysis, not just an announcement or certification. Therefore, the correct classification is MDA with high confidence.
2022-05-03 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the Interim CFO. It certifies the review and fair presentation of the annual filings for the financial year ended December 31, 2021. The document is a certification letter and does not contain actual financial statements or substantive financial data. It references the annual filings but does not include them. The document length is 3165 characters, which is relatively short and consistent with a certification letter rather than a full report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual annual report (10-K) or other financial reports.
2022-05-03 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the annual filings for the financial year ended December 31, 2021. It is a certification letter rather than the actual annual report or financial statements. The document is relatively short (3178 characters) and primarily serves as an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the report they reference (e.g., 10-K or Annual Report).
2022-05-03 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements Years Ended December 31, 2021 and 2020' and includes an Independent Auditor's Report. It contains detailed financial statements such as the Consolidated Statements of Financial Position, Loss and Comprehensive Loss, Cash Flows, and Changes in Deficiency, along with notes to the financial statements. The presence of an auditor's opinion and comprehensive financial data for a full fiscal year indicates this is a full annual financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2021
2022-05-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.